|
【结 构 式】 
|
【分子编号】62108 【品名】5-{2-ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]-3-pyridinyl}-3-ethyl-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one 【CA登记号】 |
【 分 子 式 】C21H29N7O4S 【 分 子 量 】475.57204 【元素组成】C 53.04% H 6.15% N 20.62% O 13.46% S 6.74% |
合成路线1
该中间体在本合成路线中的序号：(XXI)Coupling between pyridinecarboxylic acid (IX) and aminopyrazole (XIX) by means of EDC/HOBt leads to the diamide adduct (XX). Subsequent intramolecular cyclization of (XX) in an ethanolic solution of potassium bis(trimethylsilyl)amide at 120 C in a sealed vessel furnishes the pyrazolopyrimidinone derivative (XXI). Reaction of (R)-propylene oxide (XXII) with sodium methoxide yields (R)-1-methoxy-2-propanol (XXIII). Finally, displacement of the ethoxy group of (XXI) with the potassium alkoxide of (XXIII) gives rise to the title compound
| 【1】 Street, S.D.A.; Wood, A.; Bunnage, M.E.; Mathias, J.P. (Pfizer Inc.; Pfizer Ltd.); Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction. WO 9954333 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (IX) | 62098 | 2-ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]nicotinic acid | C14H21N3O5S | 详情 | 详情 | |
| (XIX) | 62106 | 4-amino-5-ethyl-1-methyl-1H-pyrazole-3-carboxamide | C7H12N4O | 详情 | 详情 | |
| (XX) | 62107 | N-[3-(aminocarbonyl)-5-ethyl-1-methyl-1H-pyrazol-4-yl]-2-ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]nicotinamide | C21H31N7O5S | 详情 | 详情 | |
| (XXI) | 62108 | 5-{2-ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]-3-pyridinyl}-3-ethyl-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one | C21H29N7O4S | 详情 | 详情 | |
| (XXII) | 62110 | (R)-(+)-PROPYLENE OXIDE; 1,2-Epoxypropane; R(+)-Propylene oxide; R(+)-Methyloxirane; (R)-propylene oxide; [(R-(+)-1,2-EPOXYPROPANE]; (R)-(+)-1,2-Propylene oxide; (R)-(+)-1,2-Epoxypropane | 15448-47-2 | C3H6O | 详情 | 详情 |
| (XXIII) | 62109 | (2R)-1-methoxy-2-propanol; (R)-(-)-1-Methoxy-2-propanol; (R)-(-)-1,2-Propandiol-1-monomethylether | 4984-22-9 | C4H10O2 | 详情 | 详情 |